Frank N. Hrisomalos, M.D., M.B.A.

Frank N. Hrisomalos, M.D., M.B.A.


Vitreoretinal Disease and Surgery


Nicholas F. Hrisomalos, MD PC

Services, Procedures and Patient-Care Specialties

hrisomalos_bio.jpgConditions Treated: Comprehensive medical and surgical vitreoretinal care including: Wet and Dry Macular Degeneration, Polypoidal Choroidal Vasculopathy, Diabetic Retinopathy and Diabetic Macular Edema, Retinal Vein and Artery Occlusions, Retinal Detachments, Retinal Tears and Holes, Lattice Degeneration, Macular Hole, Vitreomacular Traction, Epiretinal Membrane, Macular Telangiectasia, Central Serous Chorioretinopathy, Endophthalmitis and other bacterial, viral, and fungal eye infections, Hereditary Retinal Dystrophies and Degenerations, Retinitis Pigmentosa, Stargardt Disease, Uveitis and eye inflammation, Retinoschisis

Diagnostics: Optical Coherence Tomography (OCT), Fundus Photography (Topcon and Optos), Electroretinography, Fluorescein and ICG Angiography, B-scan Ultrasound

Procedures: Vitrectomy, Scleral Buckle, Retinal Lasers and Cryoretinopexy (freezing), Pneumatic Retinopexy, Intravitreal Injections


B.S. in Biology with High Distinction, Indiana University Bloomington, IN 2002-2006


Chief Transitional Intern, St. Vincent Hospital, Indianapolis, IN
Chief Resident in Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
Beta Gamma Sigma
Phi Beta Kappa


Internship in Transitional Medicine, St. Vincent Hospital, Indianapolis, IN 2011-2012
Residency in Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, 2012-2015


Fellowship in Vitreoretinal Disease and Surgery, Washington University in St. Louis, St. Louis, MO, 2015-2017

Board Certification

American Board of Ophthalmology, 2016

Research Studies

Dr. Hrisomalos has been a sub-investigator for the following clinical trials:

  • Intravitreal Aflibercept Injection for Radiation Retinopathy. NCT01579760
  • Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects with Severe Sepsis. NCT02576457
  • A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered by Single or Multi-Dose Intravitreal Injections(s) to Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). NCT02341560